Clinical Trials
10 trialsNCT03201965 2025-11-26
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 3 Completed
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT05260203 2024-11-06
MargheRITA
Advice Pharma Group srl
Phase NA Completed
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02574676 2019-04-09
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Prothena Biosciences Ltd.
Completed
NCT02632786 2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2 Completed
NCT01777243 2018-07-24
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
GlaxoSmithKline
Phase 1 Completed
NCT01406314 2017-06-09
SAP Depleter Dose Assessment Study in Patients
GlaxoSmithKline
Phase 1 Completed
NCT02953808 2017-01-19
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
GlaxoSmithKline
Phase 1 Completed
NCT00035334 2006-02-14
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Bellus Health Inc. - a GSK company
Phase 2/3 Completed